ALKS
Price
$29.83
Change
-$0.95 (-3.09%)
Updated
Jun 13, 04:59 PM (EDT)
Capitalization
4.55B
40 days until earnings call
LFCR
Price
$6.74
Change
-$0.09 (-1.32%)
Updated
Jun 13, 04:59 PM (EDT)
Capitalization
176.87M
75 days until earnings call
Interact to see
Advertisement

ALKS vs LFCR

Header iconALKS vs LFCR Comparison
Open Charts ALKS vs LFCRBanner chart's image
Alkermes
Price$29.83
Change-$0.95 (-3.09%)
Volume$60.24K
Capitalization4.55B
Lifecore Biomedical
Price$6.74
Change-$0.09 (-1.32%)
Volume$484
Capitalization176.87M
ALKS vs LFCR Comparison Chart
Loading...
ALKS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LFCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALKS vs. LFCR commentary
Jun 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALKS is a Hold and LFCR is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 14, 2025
Stock price -- (ALKS: $30.78 vs. LFCR: $6.83)
Brand notoriety: ALKS and LFCR are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: ALKS: 94% vs. LFCR: 23%
Market capitalization -- ALKS: $4.55B vs. LFCR: $176.87M
ALKS [@Pharmaceuticals: Other] is valued at $4.55B. LFCR’s [@Pharmaceuticals: Other] market capitalization is $176.87M. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.78B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALKS’s FA Score shows that 2 FA rating(s) are green whileLFCR’s FA Score has 1 green FA rating(s).

  • ALKS’s FA Score: 2 green, 3 red.
  • LFCR’s FA Score: 1 green, 4 red.
According to our system of comparison, ALKS is a better buy in the long-term than LFCR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALKS’s TA Score shows that 5 TA indicator(s) are bullish while LFCR’s TA Score has 5 bullish TA indicator(s).

  • ALKS’s TA Score: 5 bullish, 4 bearish.
  • LFCR’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, LFCR is a better buy in the short-term than ALKS.

Price Growth

ALKS (@Pharmaceuticals: Other) experienced а -0.71% price change this week, while LFCR (@Pharmaceuticals: Other) price change was +1.19% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was -1.09%. For the same industry, the average monthly price growth was +14.55%, and the average quarterly price growth was +67.08%.

Reported Earning Dates

ALKS is expected to report earnings on Jul 23, 2025.

LFCR is expected to report earnings on Oct 02, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (-1.09% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALKS($4.55B) has a higher market cap than LFCR($177M). ALKS YTD gains are higher at: 7.024 vs. LFCR (-8.075). ALKS has higher annual earnings (EBITDA): 519M vs. LFCR (-22.64M). ALKS has more cash in the bank: 773M vs. LFCR (4.22M). LFCR has less debt than ALKS: LFCR (157M) vs ALKS (372M). ALKS has higher revenues than LFCR: ALKS (1.66B) vs LFCR (188M).
ALKSLFCRALKS / LFCR
Capitalization4.55B177M2,571%
EBITDA519M-22.64M-2,293%
Gain YTD7.024-8.075-87%
P/E Ratio8.90N/A-
Revenue1.66B188M885%
Total Cash773M4.22M18,309%
Total Debt372M157M237%
FUNDAMENTALS RATINGS
ALKS vs LFCR: Fundamental Ratings
ALKS
LFCR
OUTLOOK RATING
1..100
7376
VALUATION
overvalued / fair valued / undervalued
1..100
99
Overvalued
93
Overvalued
PROFIT vs RISK RATING
1..100
26100
SMR RATING
1..100
3899
PRICE GROWTH RATING
1..100
5456
P/E GROWTH RATING
1..100
95
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LFCR's Valuation (93) in the Industrial Specialties industry is in the same range as ALKS (99) in the Biotechnology industry. This means that LFCR’s stock grew similarly to ALKS’s over the last 12 months.

ALKS's Profit vs Risk Rating (26) in the Biotechnology industry is significantly better than the same rating for LFCR (100) in the Industrial Specialties industry. This means that ALKS’s stock grew significantly faster than LFCR’s over the last 12 months.

ALKS's SMR Rating (38) in the Biotechnology industry is somewhat better than the same rating for LFCR (99) in the Industrial Specialties industry. This means that ALKS’s stock grew somewhat faster than LFCR’s over the last 12 months.

ALKS's Price Growth Rating (54) in the Biotechnology industry is in the same range as LFCR (56) in the Industrial Specialties industry. This means that ALKS’s stock grew similarly to LFCR’s over the last 12 months.

LFCR's P/E Growth Rating (5) in the Industrial Specialties industry is in the same range as ALKS (9) in the Biotechnology industry. This means that LFCR’s stock grew similarly to ALKS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALKSLFCR
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
69%
Bullish Trend 2 days ago
77%
Momentum
ODDS (%)
Bullish Trend 2 days ago
74%
Bearish Trend 2 days ago
73%
MACD
ODDS (%)
Bearish Trend 2 days ago
66%
Bearish Trend 2 days ago
76%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
64%
Bullish Trend 2 days ago
77%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
63%
Bearish Trend 2 days ago
75%
Advances
ODDS (%)
Bullish Trend 12 days ago
76%
Bullish Trend 18 days ago
76%
Declines
ODDS (%)
Bearish Trend 4 days ago
63%
Bearish Trend 15 days ago
77%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
76%
Aroon
ODDS (%)
N/A
Bullish Trend 2 days ago
85%
View a ticker or compare two or three
Interact to see
Advertisement
ALKS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LFCR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SKYU31.85N/A
N/A
ProShares Ultra Cloud Computing
IBMN26.73-0.01
-0.02%
iShares iBonds Dec 2025 Term Muni Bd ETF
QCON46.61-0.08
-0.18%
American Century Quality Cnvtbl Scts ETF
CIK2.89-0.01
-0.34%
Credit Suisse Asset Management Income Fund
SMLF66.44-0.39
-0.58%
iShares U.S. Small-Cap Eq Fac ETF

ALKS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALKS has been loosely correlated with VTRS. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if ALKS jumps, then VTRS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALKS
1D Price
Change %
ALKS100%
-1.35%
VTRS - ALKS
35%
Loosely correlated
+1.22%
ESPR - ALKS
34%
Loosely correlated
-0.83%
PRGO - ALKS
33%
Loosely correlated
-0.44%
DVAX - ALKS
33%
Loosely correlated
+2.16%
AMRX - ALKS
33%
Loosely correlated
+2.31%
More

LFCR and

Correlation & Price change

A.I.dvisor tells us that LFCR and SHPH have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that LFCR and SHPH's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LFCR
1D Price
Change %
LFCR100%
+1.04%
SHPH - LFCR
31%
Poorly correlated
-34.42%
OGI - LFCR
28%
Poorly correlated
N/A
AMRX - LFCR
27%
Poorly correlated
+2.31%
ALKS - LFCR
27%
Poorly correlated
-1.35%
CRON - LFCR
27%
Poorly correlated
+1.53%
More